Literature DB >> 30318503

Retrospective Comparison of Long-Term Clinical Outcomes Between Percutaneous Coronary Intervention and Medical Therapy in Stable Coronary Artery Disease With Gray Zone Fractional Flow Reserve - COMFORTABLE Retrospective Study.

Takashi Kubo1, Masahiro Takahata2, Kosei Terada3, Kazuya Mori3, Yu Arita3, Yasushi Ino1, Yoshiki Matsuo1, Hironori Kitabata3, Yasutsugu Shiono1, Kunihiro Shimamura1, Takeyoshi Kameyama1, Hiroki Emori1, Yosuke Katayama1, Takashi Tanimoto3, Takashi Akasaka1.   

Abstract

BACKGROUND: A fractional flow reserve (FFR) between 0.75 and 0.80 constitutes a "gray zone" for clinical decision-making in coronary artery disease. We compared long-term outcomes of percutaneous coronary intervention (PCI) using drug-eluting stents vs. medical therapy for coronary stenosis with gray zone FFR. Methods and 
Results: We retrospectively investigated the clinical outcomes of 263 patients with gray zone FFR: 78 patients in the PCI group and 185 patients in the medical therapy group. During a median follow-up of 3.7 years, the frequency of target vessel failure (TVF, defined as a composite of cardiac death, myocardial infarction [MI], or ischemia-driven target vessel revascularization [TVR]) was significantly lower in the PCI group compared with the medical therapy group (6% vs. 19%, hazard ratio [HR]:0.33, 95% confidence interval [CI]: 0.13-0.84, P=0.008). The frequency of a composite of cardiac death or MI was not different between the 2 groups (1% vs. 2%, HR: 0.61, 95% CI: 0.07-5.49, P=0.645). The frequency of ischemia-driven TVR was significantly lower in the PCI group compared with the medical therapy group (5% vs. 18%, HR: 0.28, 95% CI: 0.10-0.79, P=0.005).
CONCLUSIONS: In patients with gray zone FFR, compared with medical therapy, PCI decreased the frequency of TVF, which was mainly driven by a reduction in the frequency of angina or myocardial ischemia without any difference in the frequency of cardiac death or MI.

Entities:  

Keywords:  Coronary physiology; Drug-eluting stents; Fractional flow reserve; Percutaneous coronary intervention

Mesh:

Year:  2018        PMID: 30318503     DOI: 10.1253/circj.CJ-18-0672

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  4 in total

1.  Physiological Pattern of Disease Assessed by Pressure-Wire Pullback Has an Influence on Fractional Flow Reserve/Instantaneous Wave-Free Ratio Discordance.

Authors:  Takayuki Warisawa; Christopher M Cook; James P Howard; Yousif Ahmad; Shunichi Doi; Masafumi Nakayama; Sonoka Goto; Yohei Yakuta; Kenichi Karube; Matthew J Shun-Shin; Ricardo Petraco; Sayan Sen; Sukhjinder Nijjer; Rasha Al Lamee; Yuki Ishibashi; Hisao Matsuda; Javier Escaned; Carlo di Mario; Darrel P Francis; Yoshihiro J Akashi; Justin E Davies
Journal:  Circ Cardiovasc Interv       Date:  2019-05       Impact factor: 6.546

2.  Comparison of clinical outcomes following percutaneous coronary intervention versus optimal medical therapy based on gray-zone fractional flow reserve in stable angina patients with intermediate coronary artery stenosis (COMFORTABLE prospective study): Study protocol for a multicenter randomized controlled trial.

Authors:  Hironori Kitabata; Takashi Kubo; Yasutsugu Shiono; Kunihiro Shimamura; Yasushi Ino; Takashi Tanimoto; Yasushi Hayashi; Kenichi Komukai; Hiromichi Sougawa; Keizo Kimura; Masahiro Gohda; Toshikazu Hashizume; Masahiro Obana; Kazuisa Maeda; Junichi Yamaguchi; Takashi Akasaka
Journal:  Trials       Date:  2019-01-28       Impact factor: 2.279

3.  Impact of overestimation of fractional flow reserve by adenosine on anatomical-functional mismatch.

Authors:  Hidenari Matsumoto; Ryota Masaki; Satoshi Higuchi; Hideaki Tanaka; Seita Kondo; Hiroaki Tsujita; Toshiro Shinke
Journal:  Sci Rep       Date:  2022-09-02       Impact factor: 4.996

4.  Impact of Arterial Remodeling of Intermediate Coronary Lesions on Long-Term Clinical Outcomes in Patients with Stable Coronary Artery Disease: An Intravascular Ultrasound Study.

Authors:  Liang Geng; Peizhao Du; Yuan Yuan; Liming Gao; Yunkai Wang; Jiming Li; Qi Zhang
Journal:  J Interv Cardiol       Date:  2021-06-11       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.